Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol.
Sciascia S, Radin M, Cecchi I, Barinotti A, Rubini E, Rossi D, Fenoglio R, Vaccarino A, Menegatti E, Roccatello D. Sciascia S, et al. Among authors: vaccarino a. Clin Exp Rheumatol. 2023 Mar;41(3):597-604. doi: 10.55563/clinexprheumatol/qa2yb4. Epub 2022 Oct 28. Clin Exp Rheumatol. 2023. PMID: 36305361 Free article.
Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients.
Sciascia S, Radin M, Cecchi I, Bertolaccini ML, Bertero MT, Rubini E, Vaccarino A, Bazzan M, Giachino O, Baldovino S, Rossi D, Mengozzi G, Roccatello D. Sciascia S, et al. Among authors: vaccarino a. Rheumatology (Oxford). 2021 Mar 2;60(3):1106-1113. doi: 10.1093/rheumatology/kez596. Rheumatology (Oxford). 2021. PMID: 31840749
8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study.
Sciascia S, Roccatello D, Bertero MT, Di Simone D, Cosseddu D, Vaccarino A, Bazzan M, Rossi D, Garcia-Fernandez C, Ceberio L, Stella S, Menegatti E, Baldovino S. Sciascia S, et al. Among authors: vaccarino a. Inflamm Res. 2012 Aug;61(8):809-16. doi: 10.1007/s00011-012-0468-0. Epub 2012 May 26. Inflamm Res. 2012. PMID: 22638905 Free article.
Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study.
Sciascia S, Radin M, Cecchi I, Rubini E, Scotta A, Rolla R, Montaruli B, Pergolini P, Mengozzi G, Muccini E, Baldovino S, Ferro M, Vaccarino A, Mahler M, Menegatti E, Roccatello D. Sciascia S, et al. Among authors: vaccarino a. Front Immunol. 2019 Mar 5;10:376. doi: 10.3389/fimmu.2019.00376. eCollection 2019. Front Immunol. 2019. PMID: 30891041 Free PMC article.
Antiphospholipid Syndrome Is Still a Rare Disease-Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al.
Radin M, Sciascia S, Bazzan M, Bertero T, Carignola R, Montabone E, Montaruli B, Vaccarino A, Cecchi I, Rubini E, Roccatello D, Baldovino S; Piedmont and Aosta Valley APS Consortium. Radin M, et al. Among authors: vaccarino a. Arthritis Rheumatol. 2020 Oct;72(10):1774-1776. doi: 10.1002/art.41401. Epub 2020 Sep 6. Arthritis Rheumatol. 2020. PMID: 32840055 No abstract available.
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study.
Sciascia S, Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Vaccarino A, Rossi D, Roccatello D. Sciascia S, et al. Among authors: vaccarino a. Front Med (Lausanne). 2021 Feb 1;8:621590. doi: 10.3389/fmed.2021.621590. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33598471 Free PMC article.
146 results